{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:46:27Z","timestamp":1793324787759,"version":"4.5.0"},"reference-count":53,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Cardiovascular Disease"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p> Cardiac amyloidosis (CA) is a condition caused by extracellular deposition of amyloid fibrils in the heart. It is an underdiagnosed disease entity which can present with a variety of cardiac and non-cardiac manifestations. Diagnosis usually follows an initial suspicion based on clinical evaluation or imaging findings before confirmation with subsequent imaging (echocardiography, cardiac magnetic resonance imaging, 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy) in combination with biochemical screening for monoclonal dyscrasia (serum free light chains and serum and urine electrophoresis) and\/or histology (bone marrow trephine, fat or endomyocardial biopsy). More than 95% of CA can be classified as either amyloid light-chain (AL) CA or amyloid transthyretin (ATTR) CA; these two conditions have very different management strategies. AL-CA, which may be associated with multiple myeloma, can be managed with chemotherapy agents, autologous stem cell transplantation, cardiac transplant and supportive therapies. For ATTR-CA, there is increasing importance in making an early diagnosis because of novel treatments in development, which have transformed this once incurable disease to a potentially treatable disease. Timely diagnosis is crucial as there may only be a small window of opportunity where patients can benefit from treatment beyond which therapies may be less effective. Reviewing the existing patient pathway provides a basis to better understand the complexities of real-world activities which may be important to help reduce missed opportunities related to diagnosis and treatment for patients with CA. With healthcare provider interest in improving the care of patients with CA, the development of an optimal care pathway for the condition may help reduce delays in diagnosis and treatment and thus enhance patient outcomes. <\/jats:p>","DOI":"10.1177\/17539447231216318","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T09:28:49Z","timestamp":1702632529000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["The importance of pathways to facilitate early diagnosis and treatment of patients with cardiac amyloidosis"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7047-1586","authenticated-orcid":false,"given":"Chun Shing","family":"Kwok","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Hospitals of North Midlands NHS Trust, Newcastle Rd, Stoke-on-Trent ST4 6QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Moody","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospitals of Birmingham NHS Trust, Birmingham, UK"},{"name":"Chun Shing Kwok is now affiliated to Department of Cardiology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK"},{"name":"William E. Moody is also affiliated to University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"bibr1-17539447231216318","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202303210"},{"key":"bibr2-17539447231216318","first-page":"1566","volume":"10","author":"Rossi M","year":"2022","journal-title":"Biomedicine"},{"key":"bibr3-17539447231216318","unstructured":"Sham P, Ahmed I. Cardiac amyloidosis. Treasure Island, FL: StatPearls [Internet], 2023."},{"key":"bibr4-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319884371"},{"key":"bibr5-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038169"},{"key":"bibr6-17539447231216318","unstructured":"Papingiotis G, Basmpana L, Farmakis D. Cardiac amyloidosis: epidemiology, diagnosis and therapy. E-J Cardiol Pract 2021; 19. https:\/\/www.escardio.org\/Journals\/E-Journal-of-Cardiology-Practice\/Volume-19\/cardiac-amyloidosis-epidemiology-diagnosis-and-therapy"},{"key":"bibr7-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"bibr8-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319877708"},{"key":"bibr9-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"bibr10-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.03.007"},{"key":"bibr11-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000841"},{"key":"bibr12-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724"},{"key":"bibr13-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858951"},{"key":"bibr14-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"bibr15-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"bibr16-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060852"},{"key":"bibr17-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000792"},{"key":"bibr18-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13693"},{"key":"bibr19-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006913"},{"key":"bibr20-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.05.007"},{"key":"bibr21-17539447231216318","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1075806"},{"key":"bibr22-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz298"},{"key":"bibr23-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"bibr24-17539447231216318","volume":"15","author":"Elliot P","year":"2022","journal-title":"Circ Heart Fail"},{"key":"bibr25-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101358"},{"key":"bibr26-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101667"},{"key":"bibr27-17539447231216318","volume":"15","author":"Eslam RB","year":"2022","journal-title":"Circ Heart Fail"},{"key":"bibr28-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartjsupp\/suad082"},{"key":"bibr29-17539447231216318","author":"National Institute of Clinical Excellence","year":"2021","journal-title":"Technology appraisal guidance [TA696]"},{"key":"bibr30-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.012"},{"key":"bibr31-17539447231216318","unstructured":"Gillmore J. ATTRibute-CM: acoramidis (AG10) in patients with transthyretin amyloid cardiomyopathy. ESC Congress 2023, https:\/\/esc365.escardio.org\/ESC-Congress\/sessions\/7125. (accessed 4 December 2023)."},{"key":"bibr32-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"bibr33-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14285"},{"key":"bibr34-17539447231216318","unstructured":"Astrazeneca. Eplontersen met co-primary and secondary endpoints in interim analysis of the NEURO-TTRansform Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN, astrazeneca.com (2022, accessed 4 December 2023)."},{"key":"bibr35-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"bibr36-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454"},{"key":"bibr37-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303765"},{"key":"bibr38-17539447231216318","first-page":"213","volume":"20","author":"Kwok CS","year":"2021","journal-title":"Crit Pathw Cardiol"},{"key":"bibr39-17539447231216318","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10091798"},{"key":"bibr40-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-022-00551-4"},{"key":"bibr41-17539447231216318","first-page":"455","volume":"9","author":"Kwok CS","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"bibr42-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2823"},{"key":"bibr43-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2890"},{"key":"bibr44-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.11.009"},{"key":"bibr45-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.06.006"},{"key":"bibr46-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"bibr47-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac119"},{"key":"bibr48-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1186\/s44156-023-00028-7"},{"key":"bibr49-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2019.07.197"},{"key":"bibr50-17539447231216318","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0193-9"},{"key":"bibr51-17539447231216318","first-page":"20200161","volume":"7","author":"Delaney FT","year":"2021","journal-title":"BJR Case Rep"},{"key":"bibr52-17539447231216318","unstructured":"The NHS Long Term Plan. Equality and health inequalities impact assessment \u2013 Annex 1, ehia-ltp-annex.pdf (england.nhs.uk) (2019, accessed 18 July 2023)."},{"key":"bibr53-17539447231216318","first-page":"57","volume":"21","author":"Kwok CS","year":"2022","journal-title":"Crit Pathw Cardiol"}],"container-title":["Therapeutic Advances in Cardiovascular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447231216318","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17539447231216318","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447231216318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T02:40:17Z","timestamp":1740796817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17539447231216318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":53,"alternative-id":["10.1177\/17539447231216318"],"URL":"https:\/\/doi.org\/10.1177\/17539447231216318","relation":{},"ISSN":["1753-9447","1753-9455"],"issn-type":[{"value":"1753-9447","type":"print"},{"value":"1753-9455","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"17539447231216318"}}